{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:19:40Z","timestamp":1793315980566,"version":"4.5.0"},"reference-count":280,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS202300212229"],"award-info":[{"award-number":["RS202300212229"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In situ cancer vaccination, also termed intratumoral immunotherapy, transforms the tumor microenvironment into an endogenous vaccine platform by leveraging the tumor itself as a source of antigens. Unlike conventional tumor-associated antigen (TAA) or personalized neoantigen vaccines that require predefined targets and complex manufacturing, in situ cancer vaccination presents the tumor\u2019s full antigenic repertoire, including TAAs, neoantigens, post-translationally modified epitopes, cryptic peptides, and viral antigens within their native context. This broad antigen exposure elicits robust polyclonal cytotoxic T-cell responses, facilitates epitope spreading, and reduces immune escape driven by tumor heterogeneity. The therapeutic efficacy of this approach arises from the coordinated activation of multiple immune mechanisms. Programmed cell death pathways, including immunogenic apoptosis, pyroptosis, necroptosis, and ferroptosis, release tumor antigens and danger-associated molecular patterns (DAMPs) that promote dendritic-cell activation, efficient cross-presentation, and the priming of durable effector and memory T cells. The incorporation of potent adjuvants and advanced delivery platforms enhances innate-adaptive crosstalk and helps remodel the immunosuppressive tumor microenvironment. Despite these advantages, clinical translation is limited by inconsistent induction of immunogenic cell death, suboptimal intratumoral retention of therapeutics, and barriers to T-cell infiltration. Recent advances in nanomedicine-enabled delivery systems, microenvironmental modulation, and combinatorial strategies, particularly with immune checkpoint blockade, are overcoming these challenges. Collectively, these innovations position in situ cancer vaccination as a patient-tailored, broadly applicable immunotherapy capable of eliciting durable and systemic antitumor immunity.<\/jats:p>","DOI":"10.1038\/s41392-026-02821-2","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:01:42Z","timestamp":1784761302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses"],"prefix":"10.1038","volume":"11","author":[{"given":"Weihsuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwon","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyebeen","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-2990","authenticated-orcid":false,"given":"Sejin","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2821_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","volume":"9","author":"L Hammerich","year":"2015","unstructured":"Hammerich, L., Binder, A. & Brody, J. D. In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Mol. Oncol. 9, 1966\u20131981 (2015).","journal-title":"Mol. Oncol."},{"key":"2821_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2217\/imt.09.70","volume":"1","author":"S Adams","year":"2009","unstructured":"Adams, S. Toll-like receptor agonists in cancer therapy. Immunotherapy 1, 949\u2013964 (2009).","journal-title":"Immunotherapy"},{"key":"2821_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011173","volume":"13","author":"S Adams","year":"2025","unstructured":"Adams, S. et al. Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer. J. Immunother. Cancer 13, e011173 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2821_CR4","doi-asserted-by":"publisher","first-page":"1369743","DOI":"10.3389\/fimmu.2024.1369743","volume":"15","author":"G Isvoranu","year":"2024","unstructured":"Isvoranu, G. & Chiritoiu-Butnaru, M. Therapeutic potential of interleukin-21 in cancer. Front. Immunol. 15, 1369743 (2024).","journal-title":"Front. Immunol."},{"key":"2821_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160\u2013177 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2821_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","volume":"17","author":"A Lemos de Matos","year":"2020","unstructured":"Lemos de Matos, A., Franco, L. S. & McFadden, G. Oncolytic viruses and the immune system: the dynamic duo. Mol. Ther. Methods Clin. Dev. 17, 349\u2013358 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2821_CR7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814\u2013824 (2019).","journal-title":"Nat. Med."},{"key":"2821_CR8","doi-asserted-by":"publisher","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","volume":"28","author":"A Marabelle","year":"2017","unstructured":"Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral immunotherapy: using the tumor as the remedy. Ann. Oncol. 28, xii33\u2013xii43 (2017).","journal-title":"Ann. Oncol."},{"key":"2821_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/02656736.2020.1802519","volume":"37","author":"MJ Gorbet","year":"2020","unstructured":"Gorbet, M. J. et al. Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits. Int. J. Hyperth. 37, 18\u201333 (2020).","journal-title":"Int. J. Hyperth."},{"key":"2821_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"2821_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan4488","volume":"10","author":"I Sagiv-Barfi","year":"2018","unstructured":"Sagiv-Barfi, I. et al. Eradication of spontaneous malignancy by local immunotherapy. Sci. Transl. Med. 10, eaan4488 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2821_CR12","doi-asserted-by":"publisher","first-page":"188946","DOI":"10.1016\/j.bbcan.2023.188946","volume":"1878","author":"S Yu","year":"2023","unstructured":"Yu, S. et al. Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy. Biochim. Biophys. Acta Rev. Cancer 1878, 188946 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"2821_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1021\/acs.accounts.3c00771","volume":"57","author":"C Zhao","year":"2024","unstructured":"Zhao, C. et al. Nanomedicines for an enhanced immunogenic cell death-based in situ cancer vaccination response. Acc. Chem. Res. 57, 905\u2013918 (2024).","journal-title":"Acc. Chem. Res."},{"key":"2821_CR14","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","volume":"28","author":"JD Brody","year":"2010","unstructured":"Brody, J. D. et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study. J. Clin. Oncol. 28, 4324\u20134332 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2821_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2567.2004.02001.x","volume":"114","author":"MR Crittenden","year":"2005","unstructured":"Crittenden, M. R., Thanarajasingam, U., Vile, R. G. & Gough, M. J. Intratumoral immunotherapy: using the tumour against itself. Immunology 114, 11\u201322 (2005).","journal-title":"Immunology"},{"key":"2821_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","volume":"23","author":"N Gong","year":"2024","unstructured":"Gong, N. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug Discov. 23, 607\u2013625 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2821_CR17","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.3390\/nano13152225","volume":"13","author":"WS Yun","year":"2023","unstructured":"Yun, W. S. et al. Recent studies and progress in the intratumoral administration of nano-sized drug delivery systems. Nanomaterials 13, 2225 (2023).","journal-title":"Nanomaterials"},{"key":"2821_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","volume":"4","author":"J Nam","year":"2019","unstructured":"Nam, J. et al. Cancer nanomedicine for combination cancer immunotherapy. Nat. Rev. Mater. 4, 398\u2013414 (2019).","journal-title":"Nat. Rev. Mater."},{"key":"2821_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J. Hematol. Oncol. 15, 28 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2821_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct. Target. Ther. 8, 450 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2821_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2821_CR22","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","volume":"22","author":"K Peng","year":"2025","unstructured":"Peng, K., Zhao, X., Fu, Y.-X. & Liang, Y. Eliciting antitumor immunity via therapeutic cancer vaccines. Cell Mol. Immunol. 22, 840\u2013868 (2025).","journal-title":"Cell Mol. Immunol."},{"key":"2821_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12929-024-01102-w","volume":"32","author":"HC Liao","year":"2025","unstructured":"Liao, H. C. & Liu, S. J. Advances in nucleic acid-based cancer vaccines. J. Biomed. Sci. 32, 10 (2025).","journal-title":"J. Biomed. Sci."},{"key":"2821_CR24","doi-asserted-by":"publisher","first-page":"1164535","DOI":"10.3389\/fonc.2023.1164535","volume":"13","author":"M Proietto","year":"2023","unstructured":"Proietto, M. et al. Tumor heterogeneity: preclinical models, emerging technologies, and future applications. Front. Oncol. 13, 1164535 (2023).","journal-title":"Front. Oncol."},{"key":"2821_CR25","doi-asserted-by":"publisher","first-page":"102383","DOI":"10.1016\/j.ctrv.2022.102383","volume":"106","author":"H Fritah","year":"2022","unstructured":"Fritah, H., Rovelli, R., Chiang, C. L.-L. & Kandalaft, L. E. The current clinical landscape of personalized cancer vaccines. Cancer Treat. Rev. 106, 102383 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"2821_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"2821_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006628","volume":"11","author":"R Chang","year":"2023","unstructured":"Chang, R., Gulley, J. L. & Fong, L. Vaccinating against cancer: getting to prime time. J. Immunother. Cancer 11, e006628 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2821_CR28","doi-asserted-by":"publisher","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","volume":"109","author":"JL Gulley","year":"2017","unstructured":"Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl. Cancer Inst. 109, djw261 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"2821_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2821_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04504-w","volume":"21","author":"Z Sun","year":"2023","unstructured":"Sun, Z. et al. Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy. J. Transl. Med. 21, 619 (2023).","journal-title":"J. Transl. Med."},{"key":"2821_CR31","doi-asserted-by":"publisher","first-page":"2210452","DOI":"10.1002\/adma.202210452","volume":"36","author":"Y Bo","year":"2024","unstructured":"Bo, Y. & Wang, H. Biomaterial-based in situ cancer vaccines. Adv. Mater. 36, 2210452 (2024).","journal-title":"Adv. Mater."},{"key":"2821_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2821_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."},{"key":"2821_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature00858","volume":"418","author":"P Scaffidi","year":"2002","unstructured":"Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191\u2013195 (2002).","journal-title":"Nature"},{"key":"2821_CR35","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.1208347","volume":"334","author":"M Michaud","year":"2011","unstructured":"Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573\u20131577 (2011).","journal-title":"Science"},{"key":"2821_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fimmu.2013.00138","volume":"4","author":"PM Gallo","year":"2013","unstructured":"Gallo, P. M. & Gallucci, S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front. Immunol. 4, 138 (2013).","journal-title":"Front. Immunol."},{"key":"2821_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2821_CR38","doi-asserted-by":"publisher","first-page":"2437918","DOI":"10.1080\/21645515.2024.2437918","volume":"20","author":"L Dou","year":"2024","unstructured":"Dou, L. et al. Immunogenic cell death: a new strategy to enhancing cancer immunotherapy. Hum. Vaccin. Immunother. 20, 2437918 (2024).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2821_CR39","doi-asserted-by":"publisher","first-page":"2201734","DOI":"10.1002\/advs.202201734","volume":"9","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv. Sci. 9, 2201734 (2022).","journal-title":"Adv. Sci."},{"key":"2821_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic Cell Death In Cancer Therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"2821_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L. et al. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"2821_CR42","first-page":"187","volume":"74","author":"G Kroemer","year":"2024","unstructured":"Kroemer, G., Chan, T. A., Eggermont, A. M. M. & Galluzzi, L. Immunosurveillance in clinical cancer management. CA Cancer J. Clin. 74, 187\u2013202 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2821_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06712-8","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Li, X., Yang, M. & Liu, S.-B. Research progress on morphology and mechanism of programmed cell death. Cell Death Dis. 15, 327 (2024).","journal-title":"Cell Death Dis."},{"key":"2821_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4049\/jimmunol.163.1.130","volume":"163","author":"A Ronchetti","year":"1999","unstructured":"Ronchetti, A. et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163, 130\u2013136 (1999).","journal-title":"J. Immunol."},{"key":"2821_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","volume":"66","author":"B Zhou","year":"2020","unstructured":"Zhou, B. et al. Ferroptosis is a type of autophagy-dependent cell death. Semin. Cancer Biol. 66, 89\u2013100 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"2821_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jconrel.2023.10.032","volume":"364","author":"Y Sun","year":"2023","unstructured":"Sun, Y. et al. Nanomedicine-mediated regulated cell death in cancer immunotherapy. J. Control Release 364, 174\u2013194 (2023).","journal-title":"J. Control Release"},{"key":"2821_CR47","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2821_CR48","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.4161\/cbt.5.11.3456","volume":"5","author":"R Kim","year":"2006","unstructured":"Kim, R., Emi, M. & Tanabe, K. The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol. Ther. 5, 1429\u20131442 (2006).","journal-title":"Cancer Biol. Ther."},{"key":"2821_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.celrep.2016.03.037","volume":"15","author":"TL Aaes","year":"2016","unstructured":"Aaes, T. L. et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 15, 274\u2013287 (2016).","journal-title":"Cell Rep."},{"key":"2821_CR50","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"2821_CR51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","volume":"81","author":"G Li","year":"2024","unstructured":"Li, G. et al. cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors. Cell Mol. Life Sci. 81, 149 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"2821_CR52","doi-asserted-by":"publisher","first-page":"8576","DOI":"10.4049\/jimmunol.181.12.8576","volume":"181","author":"CJ Henry","year":"2008","unstructured":"Henry, C. J. et al. IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J. Immunol. 181, 8576\u20138584 (2008).","journal-title":"J. Immunol."},{"key":"2821_CR53","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.4049\/jimmunol.167.3.1179","volume":"167","author":"F Mattei","year":"2001","unstructured":"Mattei, F., Schiavoni, G., Belardelli, F. & Tough, D. F. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation1. J. Immunol. 167, 1179\u20131187 (2001).","journal-title":"J. Immunol."},{"key":"2821_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw2004","volume":"4","author":"AG Snyder","year":"2019","unstructured":"Snyder, A. G. et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci. Immunol. 4, eaaw2004 (2019).","journal-title":"Sci. Immunol."},{"key":"2821_CR55","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1021\/acsmedchemlett.9b00108","volume":"10","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. Identification of a RIP1 kinase inhibitor clinical candidate (GSK3145095) for the treatment of pancreatic cancer. ACS Med. Chem. Lett. 10, 857\u2013862 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"2821_CR56","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo, H., Callaway, J. B. & Ting, J. P. Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677\u2013687 (2015).","journal-title":"Nat. Med."},{"key":"2821_CR57","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050\u20131059 (2007).","journal-title":"Nat. Med."},{"key":"2821_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02183-9","volume":"23","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication. Mol. Cancer 23, 268 (2024).","journal-title":"Mol. Cancer"},{"key":"2821_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello, C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8\u201327 (2018).","journal-title":"Immunol. Rev."},{"key":"2821_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.492","volume":"11","author":"T Du","year":"2021","unstructured":"Du, T. et al. Pyroptosis, metabolism, and tumor immune microenvironment. Clin. Transl. Med. 11, e492 (2021).","journal-title":"Clin. Transl. Med."},{"key":"2821_CR61","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang, R. et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J. Hematol. Oncol. 13, 110 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2821_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39938-9","volume":"14","author":"F Li","year":"2023","unstructured":"Li, F. et al. mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy. Nat. Commun. 14, 4223 (2023).","journal-title":"Nat. Commun."},{"key":"2821_CR63","doi-asserted-by":"publisher","first-page":"9413","DOI":"10.1021\/acsnano.3c11023","volume":"18","author":"X Xu","year":"2024","unstructured":"Xu, X. et al. Bioorthogonal\/ultrasound activated oncolytic pyroptosis amplifies in situ tumor vaccination for boosting antitumor immunity. ACS Nano 18, 9413\u20139430 (2024).","journal-title":"ACS Nano"},{"key":"2821_CR64","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.scib.2025.04.015","volume":"70","author":"S Shao","year":"2025","unstructured":"Shao, S. et al. STING-activating pyroptotic nanoparticles for in situ pancreatic cancer vaccination and immunotherapy. Sci. Bull. 70, 1753\u20131756 (2025).","journal-title":"Sci. Bull."},{"key":"2821_CR65","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang, D., Chen, X., Kang, R. & Kroemer, G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 31, 107\u2013125 (2021).","journal-title":"Cell Res."},{"key":"2821_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05716-0","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. The interaction between ferroptosis and inflammatory signaling pathways. Cell Death Dis. 14, 205 (2023).","journal-title":"Cell Death Dis."},{"key":"2821_CR67","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nri.2016.63","volume":"16","author":"CJ Binder","year":"2016","unstructured":"Binder, C. J., Papac-Milicevic, N. & Witztum, J. L. Innate sensing of oxidation-specific epitopes in health and disease. Nat. Rev. Immunol. 16, 485\u2013497 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2821_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06807-2","volume":"15","author":"L Zeng","year":"2024","unstructured":"Zeng, L. et al. Advances in research on immunocyte iron metabolism, ferroptosis, and their regulatory roles in autoimmune and autoinflammatory diseases. Cell Death Dis. 15, 481 (2024).","journal-title":"Cell Death Dis."},{"key":"2821_CR69","doi-asserted-by":"publisher","first-page":"103255","DOI":"10.1016\/j.redox.2024.103255","volume":"75","author":"Z Feng","year":"2024","unstructured":"Feng, Z. et al. Inhibition of ferroptosis rescues M2 macrophages and alleviates arthritis by suppressing the HMGB1\/TLR4\/STAT3 axis in M1 macrophages. Redox Biol. 75, 103255 (2024).","journal-title":"Redox Biol."},{"key":"2821_CR70","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jconrel.2024.01.051","volume":"367","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Nanotechnology-enabled M2 macrophage polarization and ferroptosis inhibition for targeted inflammatory bowel disease treatment. J. Control Release 367, 339\u2013353 (2024).","journal-title":"J. Control Release"},{"key":"2821_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2618-6","volume":"11","author":"DH Kim","year":"2020","unstructured":"Kim, D. H. et al. TGF-\u03b21-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells. Cell Death Dis. 11, 406 (2020).","journal-title":"Cell Death Dis."},{"key":"2821_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31218-2","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki, B. et al. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat. Commun. 13, 3676 (2022).","journal-title":"Nat. Commun."},{"key":"2821_CR73","doi-asserted-by":"publisher","first-page":"107674","DOI":"10.1016\/j.phrs.2025.107674","volume":"214","author":"J Lan","year":"2025","unstructured":"Lan, J. et al. The dynamic role of ferroptosis in cancer immunoediting: implications for immunotherapy. Pharmacol. Res. 214, 107674 (2025).","journal-title":"Pharmacol. Res."},{"key":"2821_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53010-0","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Polymeric nanocarrier via metabolism regulation mediates immunogenic cell death with spatiotemporal orchestration for cancer immunotherapy. Nat. Commun. 15, 8586 (2024).","journal-title":"Nat. Commun."},{"key":"2821_CR75","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","volume":"9","author":"X Lang","year":"2019","unstructured":"Lang, X. et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9, 1673\u20131685 (2019).","journal-title":"Cancer Discov."},{"key":"2821_CR76","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/02656736.2020.1810333","volume":"37","author":"C Mao","year":"2020","unstructured":"Mao, C. et al. In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. Int. J. Hyperth. 37, 4\u201317 (2020).","journal-title":"Int. J. Hyperth."},{"key":"2821_CR77","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3390\/vaccines12101187","volume":"12","author":"J Lan","year":"2024","unstructured":"Lan, J. et al. Basic properties and development status of aluminum adjuvants used for vaccines. Vaccines 12, 1187 (2024).","journal-title":"Vaccines"},{"key":"2821_CR78","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/pathogens10030355","volume":"10","author":"P Nguyen-Contant","year":"2021","unstructured":"Nguyen-Contant, P., Sangster, M. Y. & Topham, D. J. Squalene-based influenza vaccine adjuvants and their impact on the hemagglutinin-specific B cell response. Pathogens 10, 355 (2021).","journal-title":"Pathogens"},{"key":"2821_CR79","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.intimp.2008.01.017","volume":"8","author":"L Habjanec","year":"2008","unstructured":"Habjanec, L., Halassy, B. & Toma\u0161i\u0107, J. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. Int. Immunopharmacol. 8, 717\u2013724 (2008).","journal-title":"Int. Immunopharmacol."},{"key":"2821_CR80","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41589-023-01538-5","volume":"20","author":"LBB Martin","year":"2024","unstructured":"Martin, L. B. B. et al. Complete biosynthesis of the potent vaccine adjuvant QS-21. Nat. Chem. Biol. 20, 493\u2013502 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"2821_CR81","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597\u20131608 (2013).","journal-title":"Nat. Med."},{"key":"2821_CR82","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492\u2013503 (2010).","journal-title":"Immunity"},{"key":"2821_CR83","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., S Arunachalam, P. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2821_CR84","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/vaccines9080820","volume":"9","author":"RR Rapaka","year":"2021","unstructured":"Rapaka, R. R., Cross, A. S. & McArthur, M. A. Using adjuvants to drive T cell responses for next-generation infectious disease vaccines. Vaccines 9, 820 (2021).","journal-title":"Vaccines"},{"key":"2821_CR85","doi-asserted-by":"publisher","first-page":"B14","DOI":"10.1016\/j.vaccine.2015.01.088","volume":"33","author":"DT O\u2019Hagan","year":"2015","unstructured":"O\u2019Hagan, D. T. & Fox, C. B. New generation adjuvants\u2013from empiricism to rational design. Vaccine 33, B14\u2013B20 (2015).","journal-title":"Vaccine"},{"key":"2821_CR86","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","volume":"10","author":"R Chen","year":"2025","unstructured":"Chen, R. et al. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct. Target. Ther. 10, 216 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2821_CR87","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1172\/JCI31720","volume":"117","author":"I Gutcher","year":"2007","unstructured":"Gutcher, I. & Becher, B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J. Clin. Invest. 117, 1119\u20131127 (2007).","journal-title":"J. Clin. Invest."},{"key":"2821_CR88","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1126\/science.1183021","volume":"327","author":"A Iwasaki","year":"2010","unstructured":"Iwasaki, A. & Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 327, 291\u2013295 (2010).","journal-title":"Science"},{"key":"2821_CR89","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1084\/jem.20021910","volume":"197","author":"JM Curtsinger","year":"2003","unstructured":"Curtsinger, J. M., Lins, D. C. & Mescher, M. F. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197, 1141\u20131151 (2003).","journal-title":"J. Exp. Med."},{"key":"2821_CR90","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ni.3123","volume":"16","author":"A Iwasaki","year":"2015","unstructured":"Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343\u2013353 (2015).","journal-title":"Nat. Immunol."},{"key":"2821_CR91","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/cancers16122211","volume":"16","author":"L Mazzoccoli","year":"2024","unstructured":"Mazzoccoli, L. & Liu, B. Dendritic cells in shaping anti-tumor T cell response. Cancers 16, 2211 (2024).","journal-title":"Cancers"},{"key":"2821_CR92","doi-asserted-by":"publisher","first-page":"218752","DOI":"10.1155\/2010\/218752","volume":"2010","author":"J Kim","year":"2010","unstructured":"Kim, J., Gambhir, V., Alatery, A. & Basta, S. Delivery of exogenous antigens to induce cytotoxic CD8+ T lymphocyte responses. J. Biomed. Biotechnol. 2010, 218752 (2010).","journal-title":"J. Biomed. Biotechnol."},{"key":"2821_CR93","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1021\/acs.macromol.2c00854","volume":"55","author":"AM Weiss","year":"2022","unstructured":"Weiss, A. M. et al. Immunostimulatory polymers as adjuvants, immunotherapies, and delivery systems. Macromolecules 55, 6913\u20136937 (2022).","journal-title":"Macromolecules"},{"key":"2821_CR94","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12, 749\u2013761 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2821_CR95","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.4161\/cbt.8.15.9133","volume":"8","author":"JP Higgins","year":"2009","unstructured":"Higgins, J. P., Bernstein, M. B. & Hodge, J. W. Enhancing immune responses to tumor-associated antigens. Cancer Biol. Ther. 8, 1440\u20131449 (2009).","journal-title":"Cancer Biol. Ther."},{"key":"2821_CR96","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","volume":"39","author":"L Zitvogel","year":"2013","unstructured":"Zitvogel, L., Galluzzi, L., Smyth, M. J. & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74\u201388 (2013).","journal-title":"Immunity"},{"key":"2821_CR97","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1756-9966-31-47","volume":"31","author":"A Shimabukuro-Vornhagen","year":"2012","unstructured":"Shimabukuro-Vornhagen, A. et al. The immunosuppressive factors IL-10, TGF-\u03b2, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J. Exp. Clin. Cancer Res. 31, 47 (2012).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2821_CR98","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nri1498","volume":"4","author":"D Gabrilovich","year":"2004","unstructured":"Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941\u2013952 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"2821_CR99","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235\u2013271 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"2821_CR100","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41551-022-00973-4","volume":"7","author":"S Son","year":"2023","unstructured":"Son, S. et al. Induction of T-helper-17-cell-mediated anti-tumour immunity by pathogen-mimicking polymer nanoparticles. Nat. Biomed. Eng. 7, 72\u201384 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"2821_CR101","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/ijms21051777","volume":"21","author":"LM Scheetz","year":"2020","unstructured":"Scheetz, L. M. et al. Synthetic HDL nanoparticles delivering docetaxel and CpG for chemoimmunotherapy of colon adenocarcinoma. Int. J. Mol. Sci. 21, 1777 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2821_CR102","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","volume":"171","author":"S Crotty","year":"2003","unstructured":"Crotty, S. et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969\u20134973 (2003).","journal-title":"J. Immunol."},{"key":"2821_CR103","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/35036600","volume":"407","author":"M Maruyama","year":"2000","unstructured":"Maruyama, M., Lam, K. P. & Rajewsky, K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 407, 636\u2013642 (2000).","journal-title":"Nature"},{"key":"2821_CR104","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","volume":"184","author":"DJ DiLillo","year":"2010","unstructured":"DiLillo, D. J., Yanaba, K. & Tedder, T. F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184, 4006\u20134016 (2010).","journal-title":"J. Immunol."},{"key":"2821_CR105","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1158\/2326-6066.CIR-17-0075","volume":"5","author":"TC Bruno","year":"2017","unstructured":"Bruno, T. C. et al. Antigen-presenting intratumoral B cells affect CD4(+) TIL phenotypes in non-small cell lung cancer patients. Cancer Immunol. Res. 5, 898\u2013907 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2821_CR106","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1294296","volume":"6","author":"G Chiaruttini","year":"2017","unstructured":"Chiaruttini, G. et al. B cells and the humoral response in melanoma: the overlooked players of the tumor microenvironment. Oncoimmunology 6, e1294296 (2017).","journal-title":"Oncoimmunology"},{"key":"2821_CR107","doi-asserted-by":"publisher","first-page":"101419","DOI":"10.1016\/j.smim.2020.101419","volume":"49","author":"JR Conejo-Garcia","year":"2020","unstructured":"Conejo-Garcia, J. R., Biswas, S. & Chaurio, R. Humoral immune responses: unsung heroes of the war on cancer. Semin. Immunol. 49, 101419 (2020).","journal-title":"Semin. Immunol."},{"key":"2821_CR108","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3389\/fimmu.2020.01610","volume":"11","author":"CC Baniel","year":"2020","unstructured":"Baniel, C. C. et al. In situ vaccine plus checkpoint blockade induces memory humoral response. Front. Immunol. 11, 1610 (2020).","journal-title":"Front. Immunol."},{"key":"2821_CR109","doi-asserted-by":"publisher","first-page":"e008636","DOI":"10.1136\/jitc-2023-008636","volume":"12","author":"R Flippot","year":"2024","unstructured":"Flippot, R. et al. B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors. J. Immunother. Cancer 12, e008636 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2821_CR110","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1158\/1078-0432.CCR-22-3168","volume":"29","author":"RE Schoen","year":"2023","unstructured":"Schoen, R. E. et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma. Clin. Cancer Res. 29, 1678\u20131688 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2821_CR111","doi-asserted-by":"publisher","first-page":"PR002","DOI":"10.1158\/1940-6215.PrecPrev22-PR002","volume":"16","author":"OJ Finn","year":"2023","unstructured":"Finn, O. J. et al. Abstract PR002: a pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer. Cancer Prev. Res. 16, PR002\u2013PR002 (2023).","journal-title":"Cancer Prev. Res."},{"key":"2821_CR112","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/onc.2012.158","volume":"32","author":"DW Kufe","year":"2013","unstructured":"Kufe, D. W. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 32, 1073\u20131081 (2013).","journal-title":"Oncogene"},{"key":"2821_CR113","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ygyno.2007.02.004","volume":"105","author":"L Wang","year":"2007","unstructured":"Wang, L. et al. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol. Oncol. 105, 695\u2013702 (2007).","journal-title":"Gynecol. Oncol."},{"key":"2821_CR114","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1039\/D2SC05639A","volume":"14","author":"C Pifferi","year":"2023","unstructured":"Pifferi, C. et al. Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen. Chem. Sci. 14, 3501\u20133513 (2023).","journal-title":"Chem. Sci."},{"key":"2821_CR115","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.484","volume":"5","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. Synthetic self-adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy. MedComm 5, e484 (2024).","journal-title":"MedComm"},{"key":"2821_CR116","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12026-014-8505-4","volume":"58","author":"MS Khodadoust","year":"2014","unstructured":"Khodadoust, M. S. & Alizadeh, A. A. Tumor antigen discovery through translation of the cancer genome. Immunol. Res. 58, 292\u2013299 (2014).","journal-title":"Immunol. Res."},{"key":"2821_CR117","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00005-019-00566-1","volume":"68","author":"A Arab","year":"2020","unstructured":"Arab, A., Yazdian-Robati, R. & Behravan, J. HER2-positive breast cancer immunotherapy: a focus on vaccine development. Arch. Immunol. Ther. Exp. 68, 2 (2020).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"2821_CR118","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0065-2776(06)90007-8","volume":"90","author":"CL Slingluff Jr.","year":"2006","unstructured":"Slingluff, C. L. Jr. et al. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv. Immunol. 90, 243\u2013295 (2006).","journal-title":"Adv. Immunol."},{"key":"2821_CR119","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"2821_CR120","first-page":"274","volume":"21","author":"X Li","year":"2023","unstructured":"Li, X. et al. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biol. Med. 21, 274\u2013311 (2023).","journal-title":"Cancer Biol. Med."},{"key":"2821_CR121","doi-asserted-by":"publisher","first-page":"1094236","DOI":"10.3389\/fimmu.2023.1094236","volume":"14","author":"G Nibeyro","year":"2023","unstructured":"Nibeyro, G. et al. Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis. Front. Immunol. 14, 1094236 (2023).","journal-title":"Front. Immunol."},{"key":"2821_CR122","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","volume":"11","author":"RG Gupta","year":"2021","unstructured":"Gupta, R. G., Li, F., Roszik, J. & Liz\u00e9e, G. Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches. Cancer Discov. 11, 1024\u20131039 (2021).","journal-title":"Cancer Discov."},{"key":"2821_CR123","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","volume":"12","author":"T Jiang","year":"2019","unstructured":"Jiang, T. et al. Tumor neoantigens: from basic research to clinical applications. J. Hematol. Oncol. 12, 93 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2821_CR124","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362.e324 (2020).","journal-title":"Cell"},{"key":"2821_CR125","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 30, 1013\u20131022 (2024).","journal-title":"Nat. Med."},{"key":"2821_CR126","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ccell.2019.06.006","volume":"36","author":"S Mereiter","year":"2019","unstructured":"Mereiter, S. et al. Glycosylation in the era of cancer-targeted therapy: where are we heading? Cancer Cell 36, 6\u201316 (2019).","journal-title":"Cancer Cell"},{"key":"2821_CR127","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","volume":"78","author":"JM Hsu","year":"2018","unstructured":"Hsu, J. M., Li, C. W., Lai, Y. J. & Hung, M. C. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res. 78, 6349\u20136353 (2018).","journal-title":"Cancer Res."},{"key":"2821_CR128","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/imm.12866","volume":"153","author":"AS Codd","year":"2018","unstructured":"Codd, A. S., Kanaseki, T., Torigo, T. & Tabi, Z. Cancer stem cells as targets for immunotherapy. Immunology 153, 304\u2013314 (2018).","journal-title":"Immunology"},{"key":"2821_CR129","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2821_CR130","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas, R. et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front. Immunol. 9, 947 (2018).","journal-title":"Front. Immunol."},{"key":"2821_CR131","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-19-0545","volume":"8","author":"A Pavlick","year":"2020","unstructured":"Pavlick, A. et al. Combined vaccination with NY-ESO-1 protein, poly-ICLC, and Montanide improves humoral and cellular immune responses in patients with high-risk melanoma. Cancer Immunol. Res. 8, 70\u201380 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2821_CR132","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","volume":"3","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer, E. A. et al. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Adv. 3, 2022\u20132034 (2019).","journal-title":"Blood Adv."},{"key":"2821_CR133","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/cancers15010138","volume":"15","author":"AK Srivastava","year":"2022","unstructured":"Srivastava, A. K., Guadagnin, G., Cappello, P. & Novelli, F. Post-translational modifications in tumor-associated antigens as a platform for novel immuno-oncology therapies. Cancers 15, 138 (2022).","journal-title":"Cancers"},{"key":"2821_CR134","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ccell.2025.03.003","volume":"43","author":"C Weller","year":"2025","unstructured":"Weller, C. et al. Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell 43, 823\u2013840.e818 (2025).","journal-title":"Cancer Cell"},{"key":"2821_CR135","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk3487","volume":"388","author":"ZA Ely","year":"2025","unstructured":"Ely, Z. A. et al. Pancreatic cancer\u2013restricted cryptic antigens are targets for T cell recognition. Science 388, eadk3487 (2025).","journal-title":"Science"},{"key":"2821_CR136","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41420-024-02185-y","volume":"10","author":"X Deng","year":"2024","unstructured":"Deng, X., Yu, Y. V. & Jin, Y. N. Non-canonical translation in cancer: significance and therapeutic potential of non-canonical ORFs, m6A-modification, and circular RNAs. Cell Death Discov. 10, 412 (2024).","journal-title":"Cell Death Discov."},{"key":"2821_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03660-y","volume":"11","author":"Y Cai","year":"2024","unstructured":"Cai, Y. et al. MHC-I-presented non-canonical antigens expand the cancer immunotherapy targets in acute myeloid leukemia. Sci. Data 11, 831 (2024).","journal-title":"Sci. Data"},{"key":"2821_CR138","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003404","volume":"9","author":"A Marcu","year":"2021","unstructured":"Marcu, A. et al. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. J. Immunother. Cancer 9, e003404 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2821_CR139","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cr.2016.153","volume":"27","author":"H Tashiro","year":"2017","unstructured":"Tashiro, H. & Brenner, M. K. Immunotherapy against cancer-related viruses. Cell Res. 27, 59\u201373 (2017).","journal-title":"Cell Res."},{"key":"2821_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08534-1","volume":"10","author":"PC Rosato","year":"2019","unstructured":"Rosato, P. C. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat. Commun. 10, 567 (2019).","journal-title":"Nat. Commun."},{"key":"2821_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).","journal-title":"Cell Death Dis."},{"key":"2821_CR142","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nri2545","volume":"9","author":"DR Green","year":"2009","unstructured":"Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353\u2013363 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2821_CR143","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74\u201380 (2015).","journal-title":"Science"},{"key":"2821_CR144","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"2821_CR145","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208\u2013220 (2016).","journal-title":"Trends Immunol."},{"key":"2821_CR146","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122, 899\u2013910 (2012).","journal-title":"J. Clin. Invest."},{"key":"2821_CR147","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723.e714 (2017).","journal-title":"Cancer Cell"},{"key":"2821_CR148","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2821_CR149","doi-asserted-by":"publisher","first-page":"1017400","DOI":"10.3389\/fimmu.2022.1017400","volume":"13","author":"D Xie","year":"2022","unstructured":"Xie, D., Wang, Q. & Wu, G. Research progress in inducing immunogenic cell death of tumor cells. Front. Immunol. 13, 1017400 (2022).","journal-title":"Front. Immunol."},{"key":"2821_CR150","doi-asserted-by":"publisher","first-page":"925290","DOI":"10.3389\/fimmu.2022.925290","volume":"13","author":"E Catanzaro","year":"2022","unstructured":"Catanzaro, E., Feron, O., Skirtach, A. G. & Krysko, D. V. Immunogenic cell death and role of nanomaterials serving as therapeutic vaccine for personalized cancer immunotherapy. Front. Immunol. 13, 925290 (2022).","journal-title":"Front. Immunol."},{"key":"2821_CR151","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado0082","volume":"10","author":"X Jiang","year":"2024","unstructured":"Jiang, X. et al. STING activation disrupts tumor vasculature to overcome the EPR limitation and increase drug deposition. Sci. Adv. 10, eado0082 (2024).","journal-title":"Sci. Adv."},{"key":"2821_CR152","doi-asserted-by":"publisher","first-page":"e29528","DOI":"10.4161\/tisb.29528","volume":"2","author":"SK Sriraman","year":"2014","unstructured":"Sriraman, S. K., Aryasomayajula, B. & Torchilin, V. P. Barriers to drug delivery in solid tumors. Tissue Barriers 2, e29528 (2014).","journal-title":"Tissue Barriers"},{"key":"2821_CR153","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrneph.2009.97","volume":"5","author":"V Sahni","year":"2009","unstructured":"Sahni, V., Choudhury, D. & Ahmed, Z. Chemotherapy-associated renal dysfunction. Nat. Rev. Nephrol. 5, 450\u2013462 (2009).","journal-title":"Nat. Rev. Nephrol."},{"key":"2821_CR154","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg, A. D. et al. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6, e1386829 (2017).","journal-title":"Oncoimmunology"},{"key":"2821_CR155","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"2821_CR156","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford, J., Dale, D. C. & Lyman, G. H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100, 228\u2013237 (2004).","journal-title":"Cancer"},{"key":"2821_CR157","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, e955691 (2014).","journal-title":"Oncoimmunology"},{"key":"2821_CR158","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1089\/ars.2009.2485","volume":"11","author":"M Wang","year":"2009","unstructured":"Wang, M. et al. Role of the unfolded protein response regulator GRP78\/BiP in development, cancer, and neurological disorders. Antioxid. Redox Signal. 11, 2307\u20132316 (2009).","journal-title":"Antioxid. Redox Signal."},{"key":"2821_CR159","doi-asserted-by":"publisher","first-page":"786","DOI":"10.4161\/onci.19750","volume":"1","author":"AD Garg","year":"2012","unstructured":"Garg, A. D., Krysko, D. V., Vandenabeele, P. & Agostinis, P. The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology 1, 786\u2013788 (2012).","journal-title":"Oncoimmunology"},{"key":"2821_CR160","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.actbio.2021.05.023","volume":"130","author":"Z Cao","year":"2021","unstructured":"Cao, Z., Li, D., Wang, J. & Yang, X. Reactive oxygen species-sensitive polymeric nanocarriers for synergistic cancer therapy. Acta Biomater. 130, 17\u201331 (2021).","journal-title":"Acta Biomater."},{"key":"2821_CR161","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1146\/annurev-biochem-061516-045037","volume":"86","author":"H Sies","year":"2017","unstructured":"Sies, H., Berndt, C. & Jones, D. P. Oxidative stress. Annu. Rev. Biochem 86, 715\u2013748 (2017).","journal-title":"Annu. Rev. Biochem"},{"key":"2821_CR162","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","volume":"48","author":"ML Circu","year":"2010","unstructured":"Circu, M. L. & Aw, T. Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 48, 749\u2013762 (2010).","journal-title":"Free Radic. Biol. Med."},{"key":"2821_CR163","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.968434","volume":"3","author":"I Adkins","year":"2014","unstructured":"Adkins, I. et al. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 3, e968434 (2014).","journal-title":"Oncoimmunology"},{"key":"2821_CR164","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1021\/acs.bioconjchem.4c00488","volume":"36","author":"S Zhan","year":"2025","unstructured":"Zhan, S. et al. Iron oxide nanoparticles induce macrophage secretion of ATP and HMGB1 to enhance irradiation-led immunogenic cell death. Bioconjug Chem. 36, 80\u201391 (2025).","journal-title":"Bioconjug Chem."},{"key":"2821_CR165","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3389\/fimmu.2018.02379","volume":"9","author":"GP Amarante-Mendes","year":"2018","unstructured":"Amarante-Mendes, G. P. et al. Pattern recognition receptors and the host cell death molecular machinery. Front. Immunol. 9, 2379 (2018).","journal-title":"Front. Immunol."},{"key":"2821_CR166","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1172\/JCI36551","volume":"120","author":"J Cherfils-Vicini","year":"2010","unstructured":"Cherfils-Vicini, J. et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest. 120, 1285\u20131297 (2010).","journal-title":"J. Clin. Invest."},{"key":"2821_CR167","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431\u2013435 (2017).","journal-title":"Nature"},{"key":"2821_CR168","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453\u2013457 (2017).","journal-title":"Nature"},{"key":"2821_CR169","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714\u2013726 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2821_CR170","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615\u2013627 (2002).","journal-title":"Annu. Rev. Med."},{"key":"2821_CR171","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482\u2013491 (2010).","journal-title":"Oncogene"},{"key":"2821_CR172","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4161\/onci.18684","volume":"1","author":"E Vacchelli","year":"2012","unstructured":"Vacchelli, E. et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 1, 271\u2013278 (2012).","journal-title":"Oncoimmunology"},{"key":"2821_CR173","doi-asserted-by":"publisher","first-page":"181","DOI":"10.18311\/ti\/2022\/v29i2\/28974","volume":"29","author":"Y Anil Kumar","year":"2022","unstructured":"Anil Kumar, Y. & Chitra, V. Prospects of combinatorial approach involving ICD induction and adenosine A2A receptor pathway inhibition to improve cancer immunotherapy. Toxicol. Int 29, 181\u2013193 (2022).","journal-title":"Toxicol. Int"},{"key":"2821_CR174","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu, A. et al. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct. Target. Ther. 9, 68 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2821_CR175","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ni.2714","volume":"14","author":"AL Doedens","year":"2013","unstructured":"Doedens, A. L. et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat. Immunol. 14, 1173\u20131182 (2013).","journal-title":"Nat. Immunol."},{"key":"2821_CR176","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374\u2013388 (2016).","journal-title":"Immunity"},{"key":"2821_CR177","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.4049\/jimmunol.180.7.4697","volume":"180","author":"J Jantsch","year":"2008","unstructured":"Jantsch, J. et al. Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J. Immunol. 180, 4697\u20134705 (2008).","journal-title":"J. Immunol."},{"key":"2821_CR178","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","volume":"72","author":"A Calcinotto","year":"2012","unstructured":"Calcinotto, A. et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 72, 2746\u20132756 (2012).","journal-title":"Cancer Res."},{"key":"2821_CR179","doi-asserted-by":"publisher","first-page":"153747","DOI":"10.1016\/j.prp.2021.153747","volume":"229","author":"X Wang","year":"2022","unstructured":"Wang, X., Wu, Y., Gu, J. & Xu, J. Tumor-associated macrophages in lung carcinoma: from mechanism to therapy. Pathol. Res. Pract. 229, 153747 (2022).","journal-title":"Pathol. Res. Pract."},{"key":"2821_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis. Oncol. 8, 31 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"2821_CR181","doi-asserted-by":"publisher","first-page":"888713","DOI":"10.3389\/fimmu.2022.888713","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao, J., Liang, Y. & Wang, L. Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front. Immunol. 13, 888713 (2022).","journal-title":"Front. Immunol."},{"key":"2821_CR182","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","volume":"150","author":"R Huang","year":"2024","unstructured":"Huang, R., Kang, T. & Chen, S. The role of tumor-associated macrophages in tumor immune evasion. J. Cancer Res. Clin. Oncol. 150, 238 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2821_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00920-x","volume":"9","author":"W Zhao","year":"2025","unstructured":"Zhao, W. et al. Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy. NPJ Precis Oncol. 9, 126 (2025).","journal-title":"NPJ Precis Oncol."},{"key":"2821_CR184","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.4049\/jimmunol.171.3.1232","volume":"171","author":"PC Rodriguez","year":"2003","unstructured":"Rodriguez, P. C. et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171, 1232\u20131239 (2003).","journal-title":"J. Immunol."},{"key":"2821_CR185","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).","journal-title":"Mol. Cancer"},{"key":"2821_CR186","doi-asserted-by":"publisher","first-page":"108114","DOI":"10.1016\/j.pharmthera.2022.108114","volume":"235","author":"S Joshi","year":"2022","unstructured":"Joshi, S. & Sharabi, A. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharmacol. Ther. 235, 108114 (2022).","journal-title":"Pharmacol. Ther."},{"key":"2821_CR187","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming, V. et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front. Immunol. 9, 398 (2018).","journal-title":"Front. Immunol."},{"key":"2821_CR188","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","volume":"35","author":"N Zhang","year":"2011","unstructured":"Zhang, N. & Bevan, M. J. CD8(+) T cells: foot soldiers of the immune system. Immunity 35, 161\u2013168 (2011).","journal-title":"Immunity"},{"key":"2821_CR189","doi-asserted-by":"publisher","first-page":"216267","DOI":"10.1016\/j.canlet.2023.216267","volume":"567","author":"R Wang","year":"2023","unstructured":"Wang, R., Liu, Z., Fan, Z. & Zhan, H. Lipid metabolism reprogramming of CD8+ T cell and therapeutic implications in cancer. Cancer Lett. 567, 216267 (2023).","journal-title":"Cancer Lett."},{"key":"2821_CR190","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1073\/pnas.96.6.3137","volume":"96","author":"PA Netti","year":"1999","unstructured":"Netti, P. A. et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA 96, 3137\u20133142 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2821_CR191","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806\u2013813 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"2821_CR192","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s11095-010-0360-y","volume":"28","author":"H Holback","year":"2011","unstructured":"Holback, H. & Yeo, Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm. Res. 28, 1819\u20131830 (2011).","journal-title":"Pharm. Res."},{"key":"2821_CR193","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00757-3","volume":"13","author":"JJ Lee","year":"2025","unstructured":"Lee, J. J., Ng, K. Y. & Bakhtiar, A. Extracellular matrix: unlocking new avenues in cancer treatment. Biomark. Res. 13, 78 (2025).","journal-title":"Biomark. Res."},{"key":"2821_CR194","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395\u2013406 (2012).","journal-title":"J. Cell Biol."},{"key":"2821_CR195","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","volume":"27","author":"Y Nakamura","year":"2016","unstructured":"Nakamura, Y., Mochida, A., Choyke, P. L. & Kobayashi, H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem. 27, 2225\u20132238 (2016).","journal-title":"Bioconjug Chem."},{"key":"2821_CR196","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","volume":"37","author":"DW Siemann","year":"2011","unstructured":"Siemann, D. W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat. Rev. 37, 63\u201374 (2011).","journal-title":"Cancer Treat. Rev."},{"key":"2821_CR197","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2017.09.016","volume":"267","author":"SM Kim","year":"2017","unstructured":"Kim, S. M., Faix, P. H. & Schnitzer, J. E. Overcoming key biological barriers to cancer drug delivery and efficacy. J. Control Release 267, 15\u201330 (2017).","journal-title":"J. Control Release"},{"key":"2821_CR198","doi-asserted-by":"publisher","first-page":"2329100","DOI":"10.1080\/10717544.2024.2329100","volume":"31","author":"K Kotani","year":"2024","unstructured":"Kotani, K., Ngako Kadji, F. M., Mandai, Y. & Hiraoka, Y. Backflow reduction in local injection therapy with gelatin formulations. Drug Deliv. 31, 2329100 (2024).","journal-title":"Drug Deliv."},{"key":"2821_CR199","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero, I. et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558\u2013576 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2821_CR200","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.molmed.2020.10.004","volume":"27","author":"CD Nishimura","year":"2021","unstructured":"Nishimura, C. D. et al. PD-L1 and B7-1 Cis-interaction: new mechanisms in immune checkpoints and immunotherapies. Trends Mol. Med. 27, 207\u2013219 (2021).","journal-title":"Trends Mol. Med."},{"key":"2821_CR201","doi-asserted-by":"publisher","first-page":"1611423","DOI":"10.3389\/fimmu.2025.1611423","volume":"16","author":"Z Shan","year":"2025","unstructured":"Shan, Z. & Liu, F. Opportunities, obstacles and challenges of nano-immunotherapy in melanoma. Front. Immunol. 16, 1611423 (2025).","journal-title":"Front. Immunol."},{"key":"2821_CR202","first-page":"100353","volume":"10","author":"S Imani","year":"2025","unstructured":"Imani, S. et al. Nanoparticle technologies in precision oncology and personalized vaccine development: challenges and advances. Int. J. Pharm. X 10, 100353 (2025).","journal-title":"Int. J. Pharm. X"},{"key":"2821_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09221-x","volume":"10","author":"X Duan","year":"2019","unstructured":"Duan, X. et al. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat. Commun. 10, 1899 (2019).","journal-title":"Nat. Commun."},{"key":"2821_CR204","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aao1736","volume":"4","author":"R Kuai","year":"2018","unstructured":"Kuai, R. et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci. Adv. 4, eaao1736 (2018).","journal-title":"Sci. Adv."},{"key":"2821_CR205","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.7150\/thno.69119","volume":"12","author":"Y Moon","year":"2022","unstructured":"Moon, Y. et al. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics 12, 1999\u20132014 (2022).","journal-title":"Theranostics"},{"key":"2821_CR206","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","volume":"22","author":"E Catanzaro","year":"2025","unstructured":"Catanzaro, E., Beltr\u00e1n-Visiedo, M., Galluzzi, L. & Krysko, D. V. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors. Cell Mol. Immunol. 22, 24\u201339 (2025).","journal-title":"Cell Mol. Immunol."},{"key":"2821_CR207","doi-asserted-by":"publisher","first-page":"216167","DOI":"10.1016\/j.canlet.2023.216167","volume":"562","author":"F Shi","year":"2023","unstructured":"Shi, F. et al. Improvement strategy for immune checkpoint blockade: a focus on the combination with immunogenic cell death inducers. Cancer Lett. 562, 216167 (2023).","journal-title":"Cancer Lett."},{"key":"2821_CR208","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3390\/ijms26041613","volume":"26","author":"V Lucarini","year":"2025","unstructured":"Lucarini, V. et al. Immunogenic cell death inducers in cancer immunotherapy to turn cold tumors into hot tumors. Int. J. Mol. Sci. 26, 1613 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2821_CR209","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02366-y","volume":"24","author":"Q Zeng","year":"2025","unstructured":"Zeng, Q. et al. Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy. Mol. Cancer 24, 176 (2025).","journal-title":"Mol. Cancer"},{"key":"2821_CR210","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02186-6","volume":"23","author":"X Ying","year":"2024","unstructured":"Ying, X. et al. Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform \u2018cold\u2019 tumors into \u2018hot\u2019 tumors. Mol. Cancer 23, 277 (2024).","journal-title":"Mol. Cancer"},{"key":"2821_CR211","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jconrel.2023.04.011","volume":"357","author":"Z Gu","year":"2023","unstructured":"Gu, Z. et al. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation. J. Control Release 357, 531\u2013544 (2023).","journal-title":"J. Control Release"},{"key":"2821_CR212","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13046-025-03520-6","volume":"44","author":"C Li","year":"2025","unstructured":"Li, C. et al. Targeting the interplay of cGAS-STING and ferroptosis by nanomedicine in the treatment of cancer. J. Exp. Clin. Cancer Res. 44, 249 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2821_CR213","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acs.nanolett.9b00021","volume":"19","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin\/JQ1. Nano Lett. 19, 2935\u20132944 (2019).","journal-title":"Nano Lett."},{"key":"2821_CR214","doi-asserted-by":"publisher","first-page":"122608","DOI":"10.1016\/j.biomaterials.2024.122608","volume":"309","author":"J Liang","year":"2024","unstructured":"Liang, J. et al. Shikonin and chitosan-silver nanoparticles synergize against triple-negative breast cancer through RIPK3-triggered necroptotic immunogenic cell death. Biomaterials 309, 122608 (2024).","journal-title":"Biomaterials"},{"key":"2821_CR215","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp7160","volume":"10","author":"G Hou","year":"2024","unstructured":"Hou, G. et al. Bimetallic peroxide nanoparticles induce PANoptosis by disrupting ion homeostasis for enhanced immunotherapy. Sci. Adv. 10, eadp7160 (2024).","journal-title":"Sci. Adv."},{"key":"2821_CR216","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005640","volume":"11","author":"C Monge","year":"2023","unstructured":"Monge, C. et al. Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. J. Immunother. Cancer 11, e005640 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2821_CR217","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00280-016-2986-x","volume":"77","author":"HA Burris","year":"2016","unstructured":"Burris, H. A. et al. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle. Cancer Chemother. Pharmacol. 77, 1079\u20131086 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2821_CR218","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00280-018-3693-6","volume":"82","author":"T Hamaguchi","year":"2018","unstructured":"Hamaguchi, T. et al. A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. Cancer Chemother. Pharmacol. 82, 1021\u20131029 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2821_CR219","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1656502","volume":"8","author":"W Xie","year":"2019","unstructured":"Xie, W. et al. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Oncoimmunology 8, e1656502 (2019).","journal-title":"Oncoimmunology"},{"key":"2821_CR220","doi-asserted-by":"publisher","first-page":"1795995","DOI":"10.1080\/2162402X.2020.1795995","volume":"9","author":"O Kepp","year":"2020","unstructured":"Kepp, O., Zitvogel, L. & Kroemer, G. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. Oncoimmunology 9, 1795995 (2020).","journal-title":"Oncoimmunology"},{"key":"2821_CR221","doi-asserted-by":"publisher","first-page":"101852","DOI":"10.1016\/j.xcrm.2024.101852","volume":"5","author":"S Chakraborty","year":"2024","unstructured":"Chakraborty, S. et al. Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Cell Rep. Med. 5, 101852 (2024).","journal-title":"Cell Rep. Med."},{"key":"2821_CR222","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/bjc.2017.205","volume":"117","author":"C Belgiovine","year":"2017","unstructured":"Belgiovine, C. et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br. J. Cancer 117, 628\u2013638 (2017).","journal-title":"Br. J. Cancer"},{"key":"2821_CR223","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing, X. et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer 18, 157 (2019).","journal-title":"Mol. Cancer"},{"key":"2821_CR224","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.2147\/IJN.S140462","volume":"13","author":"K Graham","year":"2018","unstructured":"Graham, K. & Unger, E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int. J. Nanomed. 13, 6049\u20136058 (2018).","journal-title":"Int. J. Nanomed."},{"key":"2821_CR225","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.mattod.2015.11.025","volume":"19","author":"R Mo","year":"2016","unstructured":"Mo, R. & Gu, Z. Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery. Mater. Today 19, 274\u2013283 (2016).","journal-title":"Mater. Today"},{"key":"2821_CR226","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1021\/acs.nanolett.8b00040","volume":"18","author":"G Yang","year":"2018","unstructured":"Yang, G. et al. Smart nanoreactors for pH-responsive tumor homing, mitochondria-targeting, and enhanced photodynamic-immunotherapy of cancer. Nano Lett. 18, 2475\u20132484 (2018).","journal-title":"Nano Lett."},{"key":"2821_CR227","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1039\/C7NR07677K","volume":"10","author":"H He","year":"2018","unstructured":"He, H. et al. Selective cancer treatment via photodynamic sensitization of hypoxia-responsive drug delivery. Nanoscale 10, 2856\u20132865 (2018).","journal-title":"Nanoscale"},{"key":"2821_CR228","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s40425-019-0817-4","volume":"7","author":"M Cao","year":"2019","unstructured":"Cao, M. et al. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth. J. Immunother. Cancer 7, 326 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2821_CR229","doi-asserted-by":"publisher","first-page":"120891","DOI":"10.1016\/j.biomaterials.2021.120891","volume":"275","author":"R Xie","year":"2021","unstructured":"Xie, R. et al. Furin-instructed aggregated gold nanoparticles for re-educating tumor associated macrophages and overcoming breast cancer chemoresistance. Biomaterials 275, 120891 (2021).","journal-title":"Biomaterials"},{"key":"2821_CR230","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1021\/acs.nanolett.1c00209","volume":"21","author":"B Wei","year":"2021","unstructured":"Wei, B. et al. Polarization of tumor-associated macrophages by nanoparticle-loaded Escherichia coli combined with immunogenic cell death for cancer immunotherapy. Nano Lett. 21, 4231\u20134240 (2021).","journal-title":"Nano Lett."},{"key":"2821_CR231","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1021\/acs.nanolett.9b03483","volume":"20","author":"S Son","year":"2020","unstructured":"Son, S. et al. Sugar-nanocapsules imprinted with microbial molecular patterns for mRNA vaccination. Nano Lett. 20, 1499\u20131509 (2020).","journal-title":"Nano Lett."},{"key":"2821_CR232","doi-asserted-by":"publisher","first-page":"122006","DOI":"10.1016\/j.biomaterials.2023.122006","volume":"294","author":"G Catania","year":"2023","unstructured":"Catania, G. et al. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival. Biomaterials 294, 122006 (2023).","journal-title":"Biomaterials"},{"key":"2821_CR233","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1158\/0008-5472.CAN-06-0206","volume":"66","author":"MHMGM den Brok","year":"2006","unstructured":"den Brok, M. H. M. G. M. et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 66, 7285\u20137292 (2006).","journal-title":"Cancer Res."},{"key":"2821_CR234","doi-asserted-by":"publisher","first-page":"1905758","DOI":"10.1002\/adfm.201905758","volume":"30","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. NIR\/ROS-responsive black phosphorus QD vesicles as immunoadjuvant carrier for specific cancer photodynamic immunotherapy. Adv. Funct. Mater. 30, 1905758 (2020).","journal-title":"Adv. Funct. Mater."},{"key":"2821_CR235","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","volume":"18","author":"JJ Baljon","year":"2024","unstructured":"Baljon, J. J. et al. A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists. ACS Nano 18, 6845\u20136862 (2024).","journal-title":"ACS Nano"},{"key":"2821_CR236","doi-asserted-by":"publisher","first-page":"9904","DOI":"10.1021\/acsnano.0c02765","volume":"14","author":"D Shae","year":"2020","unstructured":"Shae, D. et al. Co-delivery of peptide neoantigens and stimulator of interferon genes agonists enhances response to cancer vaccines. ACS Nano 14, 9904\u20139916 (2020).","journal-title":"ACS Nano"},{"key":"2821_CR237","doi-asserted-by":"publisher","first-page":"101797","DOI":"10.1016\/j.xcrm.2024.101797","volume":"5","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. A dual-STING-activating nanosystem expands cancer immunotherapeutic temporal window. Cell Rep. Med. 5, 101797 (2024).","journal-title":"Cell Rep. Med."},{"key":"2821_CR238","doi-asserted-by":"publisher","first-page":"eadj9366","DOI":"10.1126\/scitranslmed.adj9366","volume":"16","author":"L Chibaya","year":"2024","unstructured":"Chibaya, L. et al. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci. Transl. Med. 16, eadj9366 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2821_CR239","doi-asserted-by":"publisher","first-page":"5894","DOI":"10.1021\/acs.nanolett.4c01267","volume":"24","author":"C Gao","year":"2024","unstructured":"Gao, C. et al. Sustained secretion of CCL21 via an implantable cell reservoir hydrogel enhances the systemic antitumor effect of radiotherapy. Nano Lett. 24, 5894\u20135903 (2024).","journal-title":"Nano Lett."},{"key":"2821_CR240","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00262-025-03995-4","volume":"74","author":"Y Sun","year":"2025","unstructured":"Sun, Y. et al. A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis. Cancer Immunol. Immunother. 74, 153 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"2821_CR241","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria, S., Coleman, C. N. & Formenti, S. C. Radiotherapy: changing the game in immunotherapy. Trends Cancer 2, 286\u2013294 (2016).","journal-title":"Trends Cancer"},{"key":"2821_CR242","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74, 5458\u20135468 (2014).","journal-title":"Cancer Res."},{"key":"2821_CR243","doi-asserted-by":"publisher","first-page":"738323","DOI":"10.3389\/fonc.2021.738323","volume":"11","author":"J Hua","year":"2021","unstructured":"Hua, J. et al. Current strategies for tumor photodynamic therapy combined with immunotherapy. Front. Oncol. 11, 738323 (2021).","journal-title":"Front. Oncol."},{"key":"2821_CR244","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.3390\/cells9112432","volume":"9","author":"HS Hwang","year":"2020","unstructured":"Hwang, H. S. et al. Combination of photodynamic therapy and a flagellin-adjuvanted cancer vaccine potentiated the anti-PD-1-mediated melanoma suppression. Cells 9, 2432 (2020).","journal-title":"Cells"},{"key":"2821_CR245","doi-asserted-by":"publisher","first-page":"10647","DOI":"10.1002\/anie.202015590","volume":"60","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Biomimetic nanoemulsion for synergistic photodynamic-immunotherapy against hypoxic breast tumor. Angew. Chem. Int. Ed. Engl. 60, 10647\u201310653 (2021).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2821_CR246","doi-asserted-by":"publisher","first-page":"100685","DOI":"10.1016\/j.pmatsci.2020.100685","volume":"114","author":"J-J Hu","year":"2020","unstructured":"Hu, J.-J., Lei, Q. & Zhang, X.-Z. Recent advances in photonanomedicines for enhanced cancer photodynamic therapy. Prog. Mater. Sci. 114, 100685 (2020).","journal-title":"Prog. Mater. Sci."},{"key":"2821_CR247","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-024-01852-x","volume":"9","author":"P Lu","year":"2024","unstructured":"Lu, P. et al. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Signal Transduct. Target. Ther. 9, 166 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2821_CR248","doi-asserted-by":"publisher","first-page":"2004559","DOI":"10.1002\/adma.202004559","volume":"33","author":"G Ji","year":"2021","unstructured":"Ji, G. et al. Biopolymer immune implants\u2019 sequential activation of innate and adaptive immunity for colorectal cancer postoperative immunotherapy. Adv. Mater. 33, 2004559 (2021).","journal-title":"Adv. Mater."},{"key":"2821_CR249","doi-asserted-by":"publisher","first-page":"114064","DOI":"10.1016\/j.eurpolymj.2025.114064","volume":"235","author":"M Liu","year":"2025","unstructured":"Liu, M. et al. Multifunctional hydrogels: therapeutic strategies and advances in inflammation. Eur. Polym. J. 235, 114064 (2025).","journal-title":"Eur. Polym. J."},{"key":"2821_CR250","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas, A. et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study. Cancer Discov. 8, 1250\u20131257 (2018).","journal-title":"Cancer Discov."},{"key":"2821_CR251","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.ccell.2024.10.001","volume":"42","author":"JW Smithy","year":"2024","unstructured":"Smithy, J. W. & Postow, M. A. Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma. Cancer Cell 42, 1813\u20131814 (2024).","journal-title":"Cancer Cell"},{"key":"2821_CR252","doi-asserted-by":"publisher","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","volume":"113","author":"S Wang","year":"2016","unstructured":"Wang, S. et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc. Natl. Acad. Sci. USA 113, E7240\u2013E7249 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2821_CR253","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","volume":"8","author":"MJ Frank","year":"2018","unstructured":"Frank, M. J. et al. In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma. Cancer Discov. 8, 1258\u20131269 (2018).","journal-title":"Cancer Discov."},{"key":"2821_CR254","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","volume":"28","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas. Clin. Cancer Res. 28, 677\u2013688 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2821_CR255","doi-asserted-by":"crossref","unstructured":"M\u00e1rquez-Rodas, I. et al. BO-112 plus pembrolizumab for patients with anti\u2013PD-1\u2013resistant advanced melanoma: phase II clinical trial SPOTLIGHT-203. J. Clin. Oncol. 43, 2806\u20132815 (2025).","DOI":"10.1200\/JCO-24-02595"},{"key":"2821_CR256","first-page":"A623","volume":"10","author":"T Marron","year":"2022","unstructured":"Marron, T. et al. 595 Flt3L-primed in situ vaccination and pembrolizumab induce systemic tumor regressions of bulky tumors in patients with lymphomas and ER\/PR+ breast cancer. J. Immunother. Cancer 10, A623 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2821_CR257","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.232654","volume":"312","author":"RA Sheth","year":"2024","unstructured":"Sheth, R. A. et al. Intratumoral injection of immunotherapeutics: state of the art and future directions. Radiology 312, e232654 (2024).","journal-title":"Radiology"},{"key":"2821_CR258","doi-asserted-by":"publisher","first-page":"114505","DOI":"10.1016\/j.addr.2022.114505","volume":"189","author":"A Som","year":"2022","unstructured":"Som, A. et al. Image-guided intratumoral immunotherapy: developing a clinically practical technology. Adv. Drug Deliv. Rev. 189, 114505 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2821_CR259","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-025-01692-4","volume":"18","author":"N Liu","year":"2025","unstructured":"Liu, N. et al. Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy. J. Hematol. Oncol. 18, 45 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2821_CR260","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/ar139","volume":"3","author":"GM Deng","year":"2001","unstructured":"Deng, G. M. & Tarkowski, A. Synovial cytokine mRNA expression during arthritis triggered by CpG motifs of bacterial DNA. Arthritis Res. 3, 48\u201353 (2001).","journal-title":"Arthritis Res."},{"key":"2821_CR261","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand, U. et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 10, 1367\u20131401 (2023).","journal-title":"Genes Dis."},{"key":"2821_CR262","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","volume":"29","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam, F. et al. Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study. Clin. Cancer Res. 29, 110\u2013121 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2821_CR263","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.21037\/atm-21-491","volume":"9","author":"M Zawit","year":"2021","unstructured":"Zawit, M. et al. Current status of intralesional agents in treatment of malignant melanoma. Ann. Transl. Med. 9, 1038 (2021).","journal-title":"Ann. Transl. Med."},{"key":"2821_CR264","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1097\/MPA.0000000000002236","volume":"52","author":"NR Sharma","year":"2023","unstructured":"Sharma, N. R. et al. Response of locally advanced pancreatic cancer to intratumoral injection of large surface area microparticle paclitaxel: initial report of safety and clinical outcome. Pancreas 52, e179\u2013e187 (2023).","journal-title":"Pancreas"},{"key":"2821_CR265","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/2326-6066.CIR-14-0024","volume":"2","author":"AM Salazar","year":"2014","unstructured":"Salazar, A. M. et al. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol. Res. 2, 720\u2013724 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2821_CR266","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"2821_CR267","doi-asserted-by":"publisher","first-page":"121393","DOI":"10.1016\/j.biomaterials.2022.121393","volume":"283","author":"I Naqvi","year":"2022","unstructured":"Naqvi, I. et al. DAMPs\/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. Biomaterials 283, 121393 (2022).","journal-title":"Biomaterials"},{"key":"2821_CR268","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3389\/fimmu.2018.02619","volume":"9","author":"T Hayashi","year":"2018","unstructured":"Hayashi, T. et al. DAMP-inducing adjuvant and PAMP adjuvants parallelly enhance protective type-2 and type-1 immune responses to influenza split vaccination. Front. Immunol. 9, 2619 (2018).","journal-title":"Front. Immunol."},{"key":"2821_CR269","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1524","volume":"2","author":"S Pawaria","year":"2011","unstructured":"Pawaria, S. & Binder, R. J. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun. 2, 521 (2011).","journal-title":"Nat. Commun."},{"key":"2821_CR270","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06807-9","volume":"9","author":"DV Krysko","year":"2018","unstructured":"Krysko, D. V., Ravichandran, K. S. & Vandenabeele, P. Macrophages regulate the clearance of living cells by calreticulin. Nat. Commun. 9, 4644 (2018).","journal-title":"Nat. Commun."},{"key":"2821_CR271","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41388-023-02919-9","volume":"43","author":"HN Al-Ali","year":"2024","unstructured":"Al-Ali, H. N. et al. A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene 43, 608\u2013614 (2024).","journal-title":"Oncogene"},{"key":"2821_CR272","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1172\/JCI77014","volume":"125","author":"F Tzelepis","year":"2015","unstructured":"Tzelepis, F. et al. Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. J. Clin. Invest. 125, 752\u2013768 (2015).","journal-title":"J. Clin. Invest."},{"key":"2821_CR273","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1038\/s41388-019-0684-y","volume":"38","author":"E De Marchi","year":"2019","unstructured":"De Marchi, E. et al. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38, 3636\u20133650 (2019).","journal-title":"Oncogene"},{"key":"2821_CR274","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cdd.2013.75","volume":"21","author":"I Martins","year":"2014","unstructured":"Martins, I. et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 21, 79\u201391 (2014).","journal-title":"Cell Death Differ."},{"key":"2821_CR275","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nri749","volume":"2","author":"P Srivastava","year":"2002","unstructured":"Srivastava, P. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2, 185\u2013194 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"2821_CR276","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fimmu.2016.00201","volume":"7","author":"Y Tamura","year":"2016","unstructured":"Tamura, Y., Yoneda, A., Takei, N. & Sawada, K. Spatiotemporal regulation of Hsp90-ligand complex leads to immune activation. Front. Immunol. 7, 201 (2016).","journal-title":"Front. Immunol."},{"key":"2821_CR277","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4049\/jimmunol.1900860","volume":"205","author":"H Zhong","year":"2020","unstructured":"Zhong, H. et al. Interplay between RAGE and TLR4 regulates HMGB1-induced inflammation by promoting cell surface expression of RAGE and TLR4. J. Immunol. 205, 767\u2013775 (2020).","journal-title":"J. Immunol."},{"key":"2821_CR278","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2119\/molmed.2014.00014","volume":"20","author":"DS Pisetsky","year":"2014","unstructured":"Pisetsky, D. S. The expression of HMGB1 on microparticles released during cell activation and cell death in vitro and in vivo. Mol. Med. 20, 158\u2013163 (2014).","journal-title":"Mol. Med."},{"key":"2821_CR279","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s12276-023-00965-7","volume":"55","author":"J Kim","year":"2023","unstructured":"Kim, J., Kim, H.-S. & Chung, J. H. Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway. Exp. Mol. Med. 55, 510\u2013519 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2821_CR280","doi-asserted-by":"publisher","first-page":"155330","DOI":"10.1016\/j.prp.2024.155330","volume":"258","author":"W Li","year":"2024","unstructured":"Li, W. et al. Release of damaged mitochondrial DNA: a novel factor in stimulating inflammatory response. Pathol. Res. Pract. 258, 155330 (2024).","journal-title":"Pathol. Res. Pract."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02821-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02821-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02821-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:01:47Z","timestamp":1784761307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02821-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":280,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2821"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02821-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"289"}}